Literature DB >> 29599665

Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in 2017.

Muhammad Wasif Saif1.   

Abstract

Entities:  

Keywords:  Pancreas

Year:  2017        PMID： 29599665      PMCID： PMC5870128     

Source DB:  PubMed          Journal:  JOP        ISSN： 1590-8577


× No keyword cloud information.
  22 in total

1.  A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Authors:  Muhammad Wasif Saif; Kristin Kaley; Marianne Brennan; Marie Carmel Garcon; Gladys Rodriguez; Teresa Rodriguez
Journal:  JOP       Date:  2013-09-10

2.  Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.

Authors:  Eric H Jensen; Larry Kvols; James M McLoughlin; James M Lewis; Michael D Alvarado; Timothy Yeatman; Mokenge Malafa; David Shibata
Journal:  Ann Surg Oncol       Date:  2006-12-05       Impact factor: 5.344

3.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

4.  CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells.

Authors:  Eriko Katsuta; Shinji Tanaka; Kaoru Mogushi; Shu Shimada; Yoshimitsu Akiyama; Arihiro Aihara; Satoshi Matsumura; Yusuke Mitsunori; Daisuke Ban; Takanori Ochiai; Atsushi Kudo; Hiroshi Fukamachi; Hiroshi Tanaka; Koh Nakayama; Shigeki Arii; Minoru Tanabe
Journal:  Int J Oncol       Date:  2015-12-18       Impact factor: 5.650

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.

Authors:  F Panzuto; C Severi; R Cannizzaro; M Falconi; S Angeletti; A Pasquali; V D Corleto; B Annibale; A Buonadonna; P Pederzoli; G Delle Fave
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

8.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

Review 9.  Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

Authors:  Muhammad Wasif Saif
Journal:  Expert Opin Pharmacother       Date:  2016-01-19       Impact factor: 3.889

10.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.